Market Overview

ARIAD Presents Long-Term Durability-of-Response Data from Phase 1 Trial of Iclusig

ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term
durability-of-response data from its Phase 1 trial of Iclusig®
(ponatinib) in heavily pretreated patients with resistant or intolerant
chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL). The study shows that among
chronic-phase (CP) patients, the median durations of major and complete
cytogenetic responses, along with major molecular response, have yet to
be reached. The median follow-up for CP patients still on study is now
more than three years (36.5 months).

These data are being featured today at 8:00 a.m. CT in a poster
presentation at the Annual Meeting of the American Society of Clinical
Oncology

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters